Company Insights

NAGE customer relationships

Explore interactive graphBrowse insights index
NAGE customer relationship map

Niagen Bioscience (NAGE): Customer Footprint, Concentration Risk, and Commercial Leverage

Niagen Bioscience sells pharmaceutical-grade nicotinamide riboside and finished consumer products under a dual-channel model: B2B ingredient supply to partners and 503B compounding facilities, plus direct-to-consumer sales through TRUNIAGEN.com and major marketplaces. The company monetizes through ingredient contracts and branded product margin expansion, with a notable revenue concentration in a small number of large customers and an active clinic expansion program that converts institutional placements into recurring demand. For deeper signals on counterparties and exposures, visit NullExposure for structured relationship intelligence.

How Niagen operates and why the customer map matters

Niagen’s commercial model is one supplier / two go-to-market channels. It sells bulk NRCL and Niagen ingredient to consumer health and food partners while simultaneously scaling its Tru Niagen brand DTC and clinic distribution. The company discloses material customer concentration — two customers represented more than 10% of net sales in 2023–2024 — which directly translates to revenue sensitivity when large buyers change ordering cadence. According to the FY2024 Form 10‑K, A.S. Watson Group and Life Extension each accounted for substantial portions of net sales in 2024, underscoring this concentration risk.

Operational characteristics and contracting posture:

  • Concentration: The firm has a high concentration at the top of the revenue stack—two major customers accounted for over 10% of sales in both 2023 and 2024 (company-level disclosure, FY2024 10‑K).
  • Contracting posture: Niagen executes exclusive supply commitments in some cases — the FY2024 10‑K states NHSc and affiliates will exclusively purchase NRCL from Niagen — which creates predictable revenue but increases counterparty dependence.
  • Criticality: The company is a manufacturer and supplier of pharmaceutical-grade Niagen to FDA-registered 503B outsourcing facilities, linking its ingredient sales to clinical and injectable use cases (company disclosures, FY2024 10‑K).
  • Maturity and channel mix: The business shows mixed maturity: a stable wholesale/ingredient revenue base with expanding clinical placements and DTC growth, and public commentary cites gross margins above 60% as the business shifts toward higher-margin channels (industry coverage, FY2026 commentary).

If you want a consolidated map of counterparties and how each one affects commercial risk, see the relationship intelligence on NullExposure.

Customer roster and what each relationship means for investors

Below I list every named relationship disclosed in the provided results with a concise, investor-focused description and the source cited naturally.

Major retail and wholesale buyers

A.S. Watson Group — A.S. Watson was a related party during 2023 and part of 2024 and represented approximately 12.5% of net sales in 2024 (10‑K, FY2024). This is a top-tier revenue contributor and a concentrated source of international sales exposure.
Source: Niagen Bioscience 2024 Form 10‑K.

A.S. Watson (Hong Kong) — Corporate commentary in 2025 notes over 12% of international revenue attributed to A.S. Watson in Hong Kong, and the company referenced the duty‑free nature of that channel when discussing tariff impacts (company press commentary, FY2025).
Source: Niagen press/industry release reported on BioSpace, FY2025.

Watson’s (Hong Kong) — Management cited quarter-level B2B distribution revenue supported by partnerships “notably with Watson's in Hong Kong,” reflecting active shelf and retail placement (earnings/press remarks, FY2026).
Source: Earnings transcript press coverage, The Globe and Mail, FY2026.

Life Extension — Life Extension accounted for approximately 11.7% of net sales in 2024, marking it as a second major customer and a key wholesale partner for U.S. retail distribution (10‑K, FY2024).
Source: Niagen Bioscience 2024 Form 10‑K.

Exclusive supply and contractual commitments

NHSc — Niagen disclosed that NHSc and its affiliates will exclusively purchase NRCL from the company, an explicit exclusivity that converts production into predictable lift but concentrates counterparty risk (10‑K, FY2024).
Source: Niagen Bioscience 2024 Form 10‑K.

Legal counterparties and settlements

Elysium Health, Inc. — The parties reached a binding settlement agreement to resolve a California Action, reflecting legal closure of a previously litigated commercial dispute (10‑K, FY2024). Investors should treat this as a legal risk resolved through settlement rather than ongoing litigation expense.
Source: Niagen Bioscience 2024 Form 10‑K.

Ingredient partners and strategic channel alliances

Nestlé (NSRGY) — Industry commentary highlights Niagen’s strategy of selling ingredients to large partners such as Nestlé, supporting operating leverage as ingredient sales complement DTC margins (market analysis, FY2026).
Source: Market commentary on Finviz, FY2026.

Thorne — Thorne is cited as an ingredient partner that supports Niagen’s dual-channel strategy and margin expansion, reinforcing the company’s B2B footprint in nutraceutical supply (industry analysis, FY2026).
Source: Market analysis on Finviz, FY2026.

LGC (LGCB) — News reports in 2026 announced the sale of Niagen’s Chromadex reference standards business to LGC in an all‑cash transaction, signaling a portfolio simplification and focus on core ingredient and branded product lines (press reporting, FY2026).
Source: Reuters/TradingView coverage and Finviz, FY2026.

Marketplaces and e‑commerce distribution

Amazon (AMZN) — Niagen distributes direct to consumers through TRUNIAGEN.com and major online marketplaces like Amazon, forming a critical retail channel for DTC volume growth (industry interview/coverage, FY2026).
Source: Directorstalk Interviews coverage, FY2026.

Clinic roll‑outs and clinical channel partners

Niagen has rapidly expanded clinical distribution for Niagen Plus products and pharmaceutical-grade offerings; the following clinic providers were named in 2025 press releases as new placements or clinical partners:

iCRYO — More than 50 iCRYO centers are carrying Niagen Plus products, part of a rollout into over 900 wellness clinics (RTTNews and press coverage, FY2025).
Source: RTTNews and associated news reports, FY2025.

LifeMed Institute — Named among new clinic providers in the company’s 2025 press release announcing pharmaceutical-grade placements (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Navo — Identified as a New York clinic provider included in the 2025 clinic expansion list (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

PEAQ Society — Listed as a new clinic provider in Kansas City for Niagen pharmaceutical-grade products (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Longevity LA — Included in the 2025 list of new clinic partners in Los Angeles (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Arete — Named as a Nashville clinic partner in the 2025 clinic rollout (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Beautologie — Identified as a Bakersfield clinic provider in the 2025 announcement (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Beyond Remedi — Included among new clinic providers in Saint Paul in 2025 (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Clarus Health — Named as a San Francisco clinic provider in the company’s clinic expansion communication (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Energy4Life Centers — Listed as a Park City clinic provider in 2025 materials (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Hydra Heal — Identified as a Newport Beach clinic provider in 2025 (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

Kahala Clinic — Named as a Honolulu partner in the clinic expansion list (press release, FY2025).
Source: Yahoo Finance press release, FY2025.

What investors should take away

  • Concentration is the central commercial risk: two customers individually exceeded 10% of sales in FY2024, and A.S. Watson remained a top international account (FY2024 10‑K).
  • Selective exclusivity drives predictability and exposure: NHSc’s exclusive NRCL commitment converts production into contracted revenue, increasing both stability and counterparty concentration (FY2024 10‑K).
  • Channel diversification is real but incomplete: the company’s clinic rollouts and DTC/marketplace presence reduce single-counterparty dependency over time, but near-term earnings remain sensitive to large wholesale contracts (company filings and press, FY2024–FY2026).

For an integrated view that maps these counterparties to exposure metrics and contract terms, check the relationship profiles on NullExposure.

Actionable next steps for investors

  • Monitor order cadence from A.S. Watson and Life Extension in quarterly disclosures and MD&A for signs of material re‑pricing or shifts in allocation.
  • Track exclusivity performance with NHSc and any renewal or termination language disclosed in future 10‑Qs or press releases.
  • Watch clinic penetration metrics and DTC growth as indicators of margin expansion and reduced customer concentration risk.

To access consolidated counterparty summaries and to receive alerts on material changes to Niagen’s customer roster, visit NullExposure.